Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

Trial ID or NCT#

NCT00350142

Status

not recruiting iconNOT RECRUITING

Purpose

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Official Title

Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer

Eligibility Criteria

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Pancreatic tumors not to exceed 10 cm in greatest axial dimension - Histologically confirmed malignancies of the pancreas - Unresectable by CT criteria or exploratory laparotomy or laparoscopy - Patients with metastatic disease may be treated if they are symptomatic from the primary tumor - Performance status of 0, 1, or 2 - No chemotherapy two weeks prior or two weeks following radiosurgery
Exclusion Criteria:
  1. - patients who have had prior radiotherapy to upper abdomen - patients receiving any prior pancreatic cancer therapy - children, pregnant, and breastfeeding women, and lab personnel are excluded - uncontrolled intercurrent illnesses - any concurrent malignancy
View All Criteria
Show Less

Investigator(s)

Jeffrey Norton, MD
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.

Contact

Jeff Kim
6504987703

View on ClinicalTrials.gov